A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor JAMA DERMATOLOGY Chang, A. S., Kim, J., Luciano, R., Sullivan-Chang, L., Colevas, A. D. 2016; 152 (1): 106–8

View details for PubMedID 26422398